A Trial In Patients With Advanced Cancer And Leukemia

A PHASE I TRIAL OF PF-03084014 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCY AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA

This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia

Inclusion Criteria:

• Patients with advanced cancer that is resistant to standard therapy or for which no standard therapy is available
• Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to standard therapy or for which no standard therapy is available
• Men and women >16 years old

Exclusion Criteria:

• Prior treatment with a gamma secretase inhibitor for treatment of cancer
• Patients taking Tamoxifen
• Patients with active graft versus host disease
• Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
• Patients who are pregnant or breast feeding
• Patients with clinical evidence of central nervous system disease